WO2008002484A2 - Nouvelle souche de lactobacillus bulgaricus et compositions la contenant - Google Patents

Nouvelle souche de lactobacillus bulgaricus et compositions la contenant Download PDF

Info

Publication number
WO2008002484A2
WO2008002484A2 PCT/US2007/014584 US2007014584W WO2008002484A2 WO 2008002484 A2 WO2008002484 A2 WO 2008002484A2 US 2007014584 W US2007014584 W US 2007014584W WO 2008002484 A2 WO2008002484 A2 WO 2008002484A2
Authority
WO
WIPO (PCT)
Prior art keywords
probiotic composition
bulgaricus
ssp
lactobacillus delbrueckii
forming units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/014584
Other languages
English (en)
Other versions
WO2008002484A3 (fr
Inventor
Gregory G. Bojrab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lacpro Industries LLC
Original Assignee
Lacpro Industries LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/473,654 external-priority patent/US7901925B2/en
Priority claimed from US11/473,468 external-priority patent/US20070298018A1/en
Application filed by Lacpro Industries LLC filed Critical Lacpro Industries LLC
Publication of WO2008002484A2 publication Critical patent/WO2008002484A2/fr
Publication of WO2008002484A3 publication Critical patent/WO2008002484A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/137—Delbrueckii
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the present application relates generally to a novel organism strain, compositions comprising the novel organism, and methods of using the organism as a probiotic.
  • Probiotics are defined by the World Health Organization as "live microorganisms, which when administered in adequate amounts confer a health benefit on the host.” BACKGROUND
  • the human digestive tract is an ecosystem unto itself, containing a complex diversity of beneficial and harmful bacteria, with over 400 different bacteria species being found in the intestine alone.
  • This diverse intestinal microflora plays a substantial role in regulating intestinal barrier defense mechanism, and effectively comprises approximately 80% of our immune system.
  • Ongoing research continues to support the theory that appropriate microbial balance in the intestine greatly enhances the general health and immune system of a person or animal when compared to another individual lacking such a balance.
  • a healthy population of beneficial, mutualistic, and/or commensal microorganisms in the digestive tract play a substantial role in maintaining the health and welfare of the host organism.
  • Such microorganisms create benefits to their hosts in many ways: through competition with pathogenic microorganisms, aiding in the digestion and absorption of food, helping with vitamin synthesis, and regulating immune responses. Therefore, healthy individuals often display a robust collection of beneficial microorganisms in their digestive systems, which aid them in maintaining a disease free state, and further contribute to the overall well-being of the individual.
  • disruptive events can lead to an imbalance in the ecology of the digestive tract, leading to a non-ideal balance of diversity and populations of beneficial microorganisms therein.
  • disruptive events include illnesses caused by exposure to viruses or pathogenic microorganisms; exposure to certain pharmaceuticals, including antibiotics; exposure to high levels of mental, physical, or emotional stress, including surgical complications or excessive travel; and improper nutrition or malnutrition.
  • studies have shown that as individuals age, the stability of the delicate balance of intestinal flora declines, which can lead to an unhealthy imbalance in the digestive tract that may weaken the immune system and/or give rise to the possibility of infection, autoimmune dysfunction, and several surprising downstream biological system problems.
  • a healthy, balanced digestive tract flora is important to ensure that an individual maintains a state of health. Further, it has been shown that the use of transitory microorganisms, or microorganisms that are not commonly found in the digestive tract, but may be introduced for short periods of time, can help restore a balance of beneficial flora in otherwise healthy individuals, can combat pathogenic microorganisms and viruses, and can cause surprising positive effects in a host.
  • 6,696,057 discusses the successful use of a probiotic composition comprising two microorganisms that has been shown to reduce hyperlipidemia (high cholesterol); combat autoimmune diseases; alleviate Irritable Bowel Syndrome, Inflammatory Bowel Disease, and diarrhea; reduce the symptoms of Crohn's disease; and treat ulcerative colitis.
  • hyperlipidemia high cholesterol
  • combat autoimmune diseases alleviate Irritable Bowel Syndrome, Inflammatory Bowel Disease, and diarrhea
  • reduce the symptoms of Crohn's disease and treat ulcerative colitis.
  • the use of such probiotic compositions were far less expensive, showed fewer side effects in the individuals tested, and showed the positive side effect of reducing inflammatory response in the digestive tract, which may aid in a reduction of the risk of colorectal cancer or other diseases.
  • composition disclosed in United States Patent No. 6,696,057 and comprising Streptococcus thermophilus and Lactobacillus delbrueckii, ssp. bulgaricus (also referred to as "Lactobacillus bulgaricus”) has been shown to be effective, finding and maintaining ideal culture conditions to maximize production of these two different species in a consumable media can be difficult.
  • ssp. bulgaricus also referred to as "Lactobacillus bulgaricus”
  • the present application relates to an isolated strain of Lactobacillus, compositions including the strain or culture, and methods for its use. Specifically, according to one embodiment, the present application relates to an isolated culture of a bacterial strain Lactobacillus delbrueckii, ssp. bulgaricus having accession number NRRL B-30892. According to one aspect, the isolated culture described may further be placed in freeze-dried form.
  • the isolated culture may comprise at least 3 x 10 el 0 colony forming units. Further, the isolated culture may further comprise a culture media that can increase the CFU of the isolated culture.
  • One embodiment utilizes a dairy product, while other embodiment use animal or plant-based milk products.
  • one embodiment of the present application relates to an isolated culture of a bacterial strain of the genus Lactobacillus, with the following characteristics as exhibited by the culture deposited in the Agricultural Research Service Patent Culture Collection and given the NRRL Accession Number B-30892: efficiency in multiplying in dairy products and an ability to continue production of colony forming units below a pH of 4.5.
  • the present application involves a probiotic composition comprising the bacteria strain described within this application, along with a delivery mechanism.
  • the delivery mechanism comprises a carbohydrate-containing medium operable to increase the culture size of an inoculation dose of the bacteria described herein.
  • the inoculation dose may increase in size to a therapeutic dose of the bacteria described herein in the carbohydrate-containing medium.
  • the carbohydrate- containing medium is optionally a milk-based product and the milk-based product can optionally be a vegetable milk or a milk derived or taken from an animal.
  • one embodiment utilizes at least about 1.3 x lOelO CFU as a therapeutic dose of the bacteria strain described herein.
  • Other embodiments utilize at least about 3 x lOelO colony forming units as a therapeutic dose.
  • varying different volumes of the probiotic composition may include a therapeutic dose of the bacteria strain.
  • the therapeutic dose of the bacteria strain is found in about 10 ounces or less or the composition.
  • the therapeutic dose may be about 8 ounces or less of the composition, or 3 ounces or less of the composition.
  • the probiotic composition displays the characteristic of alleviating symptoms of a diseased state.
  • the probiotic composition may provide alleviation of symptoms of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, diarrhea, hyperlipidemia, hypovitaminosis, antibiotic-associated diarrhea, or CDAD.
  • other delivery mechanisms may be used, such as utilizing a container operable to maintain the bacteria strain in a freeze-dried form, or in which the bacteria may be encapsulated for ingestion.
  • the present application relates to a method for augmenting an animal's immune system, the method comprising the steps of providing a therapeutically effective amount of a probiotic composition comprising the bacteria strain described herein and administering the therapeutically effective amount of the bacteria to the animal through ingestion.
  • a therapeutically effective amount of the probiotic composition is an amount sufficient to prevent an establishment of pathogenic organisms in the animal for a predetermined period of time.
  • the therapeutically effective amount of the bacteria comprises a range of about 1.5 x lOelO to about 5 x 1OeIO colony forming units.
  • the therapeutically effective amount of the bacteria may be further mixed within a carbohydrate enriched media.
  • the therapeutically effective amount of the bacteria when mixed with the carbohydrate enriched media, comprises approximately 10 ounces or less.
  • the effective amount of the bacteria is administered to the animal at least twice per day. Optionally, at least three hours may elapse between each administration of the therapeutically effective amount of the bacteria.
  • the method includes the step of providing an animal showing symptoms of gastrointestinal disorders, hyperlipidemia, or autoimmune diseases.
  • the method includes the step of providing an animal showing symptoms of a diseased state selected from the group consisting of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, diarrhea, and CDAD.
  • the present application relates to a method for augmenting an animal's immune system, the method comprising the steps of providing a probiotic composition comprising at least 3 x lOelO CFU of the bacteria described herein, and not more than 12 ounce of a carbohydrate-containing medium, administering the probiotic composition to an animal showing symptoms of at least one diseased state selected from the group consisting of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, diarrhea, and CDAD, and repeating administration of the probiotic composition at least twice daily at least until subsistence of the symptoms, with repeated administration occurring at an interval not less than two hours after a previous administration of the probiotic composition.
  • the carbohydrate-containing medium is a milk-based product operable to increase an inoculating colony of the bacteria to at least 3 x lOelO CFU of the bacteria per less than about twelve ounce of the carbohydrate-containing medium.
  • the probiotic composition is a cultured beverage or smoothie.
  • Yet another embodiment involves a method of treating a diseased state in a patient using a probiotic composition, with the method comprising the following steps: providing a probiotic composition comprising a specified number of CFU of the bacteria described herein, a carbohydrate-containing medium wherein the specified CFU of the bacteria are combined and allowed to ferment until a desired number of total CFU per dose is achieved; administering the probiotic composition to a patient showing symptoms of at least one diseased state selected from the group consisting of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, diarrhea, hyperlipidemia, hypovitaminosis, autoimmune disease, and CDAD; selecting a dosing form of the probiotic composition; determining an initial dosing number of CFU of the bacteria for a given dose; determining an initial dosing frequency; determining the efficacy of the probiotic composition in treating the patient's disease or diseased state; adjusting the dosing number, if required, to effectuate positive results in the patient; and adjusting
  • the initial dosing number of colony forming units per dose may range from about 1 x 1OeIO to about 6 x 10el0.
  • the initial dosing number of CFU is about 3 x 1Oe 10.
  • the dosing form may be a cultured beverage. Further, the dosing form may optionally be chosen from packets, capsules, tablets, or caplets.
  • BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a line diagram showing the relative rates of lactic acid formation capability of three strains of Lactobacillus delbrueckii, ssp. bulgaricus, including the novel strain described herein.
  • Fig. 2 is a line diagram showing the relative rates of colony increasing capability of three strains of Lactobacillus delbrueckii, ssp. bulgaricus, including the novel strain described herein. DESCRIPTION
  • the present application relates to a unique strain of Lactobacillus bacteria deposited in the Agricultural Research Service Patent Culture Collection and given the NRRL Accession No. B-30892.
  • the unique strain discovered in the inventor's cultured beverage (or smoothie) cultures, has been identified as Lactobacillus delbrueckii, ssp. bulgaricus, and displays several unique characteristics when compared to other known species or strains of lactic acid producing bacteria.
  • Fig. 1 a comparison graph showing the results of culturing three strains of Lactobacillus bulgaricus in bovine milk at a temperature of 40° Celsius, each of the three strains, designated as (1) "ATTC 11842" for a previously registered strain having the accession number ATTC 11842; (2)"Lactinex” for the commercially available strain that is readily available, and (3) "FB” for the strain according to the present application, having accession number NRRL B-30892 .
  • accession number NRRL B-30892 accession number
  • L. bulgaricus FB reached the targeted pH of 4.41 after 16.5 hours. It also yielded the second highest counts. Die off for FB occurred at pH of 4.45. L. bulgaricus ATTC 11842 reached the targeted pH last (after about 17.75hrs) and yielded the lowest counts. It showed a die off after pH of 4.51. Lactinex reached the targeted pH the fastest after about 9.5 hours and yielded the highest counts. It also demonstrated a die off after pH of 4.50.
  • the strain according to the current application is unique with regard to its biological activity rate.
  • Fig. 2 a graphical comparison of the count versus time displayed by the three strains disclosed above, the three strains were cultured under conditions identical to those described above. Table 2 below shows the values plotted to obtain the graphical results in Fig. 2. As can be seen, each of the strains show significantly different rates of reproduction from one another, with a distinctly different time at which die-off occurs.
  • the FB strain of Lactobacillus bulgaricus has shown biological activity within the digestive system of mammals in general, and humans in particular. Specifically, while the FB strain has shown itself to be a transitory inhabitant of the intestinal tract, it displays the ability to disrupt the bloom of pathogenic bacteria within the intestines of its host, decreases inflammatory response- to irritants, may increase vitamin absorption, and shows general activity similar to those noted in the prior compositions discussed in United States Patent No. 6,696,057, incorporated by reference herein. II.
  • the probiotic composition comprises a therapeutically effective number of colony forming units ("CFU's") of a Lactobacillus bacteria deposited in the Agricultural Research Service Patent Culture Collection and given the NRKL Accession No. B-30892 (also referred to herein as "Lactobacillus delbrueckii, ssp. bulgaricus 1 FB'" or “Lactobacillus bulgaricus 'FB”)'.
  • the probiotic composition optionally is a freeze-dried or frozen, composition comprising the Lactobacillus bulgaricus 1 FB' in a therapeutically effective amount.
  • a therapeutically effective amount of the Lactobacillus bulgaricus 'FB' comprises approximately 1 x 10e6 to about 2 x 10el2 CFU's of the bacteria. Further optionally, a therapeutically effective amount of the bacteria comprises about more than 1 x 1Oe 10 CFU's, about more than 2 x lOelO CFU's, about more than 3 x 1Oe 10 CFU's, and/or about more than 4 x 1Oe 10 CFU's of the bacteria. In one embodiment, a therapeutically effective amount may comprise 6 x lOelO CFU's per day, and may be reached by dosing more than once per day.
  • a therapeutically effective amount may describe the concentration of the Lactobacillus bulgaricus 'FB' in a given media.
  • a therapeutically effective amount of Lactobacillus bulgaricus 'FB' may occur in a concentration about 1.3 x 10e8 CFU or more per gram of carbohydrate containing medium.
  • a therapeutically effective concentration may be about 1.3 x 10e8 or less CFU per gram of carbohydrate-containing medium.
  • the probiotic composition further comprises a carbohydrate-containing media whereby the Lactobacillus bulgaricus 'FB' strain is mixed into the carbohydrate-containing media.
  • a therapeutically effective amount of the bacteria is mixed with a given volume of the carbohydrate-containing media.
  • an inoculating culture of the bacteria is added to the carbohydrate-containing media and conditions are provided so that the Lactobacillus bulgaricus 'FB' ferments the carbohydrate-containing media and increases the number of CFU's to at least a therapeutically effective amount of the bacteria.
  • the carbohydrate- containing media may be milk or a milk product obtained from a lactating animal, a vegetable based milk or juice such as soy milk or carrot juice, may be a fruit juice or fruit drink, or any other carbohydrate-containing media.
  • the therapeutically effective number of bacteria is present in less than 24 fluid ounces of the carbohydrate-containing media. According to yet another embodiment, the therapeutically effective number of bacteria is present in less than 16 fluid ounces of the carbohydrate-containing media. Further according to yet another embodiment, the therapeutically effective number of bacteria is present in less than 12 fluid ounces of the carbohydrate-containing media. According to another embodiment, the therapeutically effective number of bacteria is present in less than 10 fluid ounces of the carbohydrate- containing media, or less than or equal to 8 fluid ounces of the carbohydrate-containing media. Finally, according to another embodiment, the therapeutically effective number of bacteria is present in less than 3.3 ounces of the carbohydrate-containing media.
  • Lactobacillus bulgaricus 1 FB' may be cultured by inoculating a large volume of the carbohydrate containing media under the proper conditions with less than 1% (by volume), less than or equal to 0.10% (by volume), or 0.05% (by volume) of concentrated Lactobacillus bulgaricus 1 FB.
  • Table 4 shows the count versus time of CFU's formed at various inoculation rates, from frozen concentrated culture, in bovine milk at 40° Celsius. The composition is optionally fermented until the CFU's per target unit volume exceeds a therapeutically effective amount of the bacteria.
  • the carbohydrate-containing medium comprises any such media common in the art.
  • the carbohydrate-containing medium is an animal or plant-based milk.
  • reconstituted powdered bovine milk is used in one embodiment as the carbohydrate-containing media such that fermentation of the carbohydrate containing media results in a cultured beverage (or smoothie) with at least a 84
  • a probiotic composition is created with enough CFU's of the bacteria so that an therapeutically effective number of bacteria are available per target volume of the probiotic composition when it is administered to an individual.
  • the probiotic composition can take the final form of either liquid, solid, or semi-solid.
  • the probiotic composition may be a set or creamy cultured beverage (or smoothie).
  • the probiotic composition may also be lyophilized and separated into specific dosing units.
  • the dosing units may be packaged in one of several forms including but not limited to packets, capsules, tablets, or caplets. Any other packaging form as is common in the art may be utilized.
  • the probiotic composition may be concentrated after fermentation is complete and then lyophilized prior to packaging. Prior to concentrating and lyophilizing the probiotic composition, the fermented end product can be packaged as a cultured beverage (or smoothie) as is typical in the art. After concentrating and lyophilizing, the probiotic composition can be packaged into desired dosing units.
  • the packaged dosing units may be in any suitable form as is common in the art and can include, but not be limited to packets, capsules, caplets, or tablets.
  • the abovementioned Lactobacillus delbrueckii, ssp. bulgaricus bacterium given the NRRL Accession No. B- 30892 and/or a probiotic composition according to one of the embodiments above is administered to an individual.
  • the bacteria or probiotic is administered as part of a method for treating gastrointestinal disorders, hyperlipidemia, Irritable Bowel Syndrome, Inflammatory Bowel Disease, diarrhea; C. difficile associated disorders, antibiotic-associated diarrhea, Crohn's disease, ulcerative colitis, or an autoimmune disease.
  • the bacteria or probiotic is administered as part of a method for boosting the immune system.
  • the method comprises the steps of providing a probiotic composition as disclosed above.
  • the method further comprises administering the probiotic composition to an individual.
  • the method optionally comprises selecting a dosing form of the probiotic composition and determining an initial dosing strength and initial dosing frequency.
  • a therapeutically effective number of CFU's of the bacteria is selected for, as well as a target volume of a dosing media to determine dosing strength.
  • the dosing media may simply be freeze dried or frozen forms of the bacteria, and is optionally contained in a capsule or in a vial that allows consumption of the bacteria.
  • the dosage strength of the composition is determined by the number of CFU's of the bacteria per unit volume of a carbohydrate-containing medium.
  • one initial dosing strength is more than 3 x lOelO CFU's per 10 ounces of carbohydrate containing media.
  • Another exemplary embodiment involves administering the aforementioned initial dosing strength at least twice per day, with the doses taken at least three hours between each administration.
  • yet an additional step in the method comprises determining the effectiveness of the probiotic composition in treating the patient. One optional step following this determination is to adjust both the dosing strength and the dosing frequency if positive results are not observed.
  • determining the efficacy of the probiotic composition is determined by at least one option chosen from evaluating the improvement of the patient's clinical symptoms, or evaluating medically standard objective parameters as appropriate for a particular disorder.
  • Such medically standard objective parameters include, but are not limited to, gastrointestinal imaging using, for example, endoscopy and barium x-ray studies, biopsy, histopathology, restoration of fluid and electrolyte balance, normalization of white blood count, serial stool analysis, and checking fasting plasma LDL, HDL and triglycerides.
  • the probiotic composition or the bacteria is optionally administered when a patient shows no signs of disease or improper health. Such preventative administration is given in order to maintain or ensure proper health through maintaining a balance within the flora of the digestive system.
  • the following examples are given as situations in which the probiotic composition is effective or anticipated to be effective.
  • Example 1 A 40 year old female presented with a three-week history of watery diarrhea after being released from the hospital for a procedure to her skull. While the patient could not remember whether an antibiotic was administered to her during hospitalization, she had self- administered Imodium and Lactobacillus acidophilus without improvement of her symptoms.
  • Clostridium difficile was confirmed in her system, indicating that the diarrhea was C. difficile associated disease (CDAD).
  • CDAD C. difficile associated disease
  • a 10 day administration of metronidazole at 500 mg was administered three times per day with little positive effect.
  • a probiotic composition according to the present application as described heretofore was administered for 10 days, twice daily with a CFU count of 5 x lOelO per dose (or 5xl ⁇ e9 CFU per gram).
  • a complete resolution of the symptoms was observed in the patient, with no relapses in over one year.
  • Example 1 A 64 year old female presented with a 10 day history of watery diarrhea, cramping, and flatus, which was confirmed to be caused by CDAD by way of a C. difficile toxin assay. Consistent with Example 1, metronidazole was prescribed for 10 days, with no improvements. Further similarly to Example 1, a probiotic composition according to the present application as described heretofore was administered for 10 days, twice daily with a CFU count of 5 x lOelO per dose (or 5xl ⁇ e9 CFU per gram). The patient improved initially, but had recurrence of diarrhea after having levaquin administered for a urinary tract infection. Continued dosing with the probiotic composition partially alleviated the diarrhea suspected as a result of recurrent CDAD. Additional medication with Fibercon and levsinex finally alleviated the remaining diarrhea symptoms, suspected to be associated with a flare up of irritable bowel syndrome.
  • Plavix® as treatment for transient ischemic attacks.
  • CDAD chronic ischemic disease
  • Example 1 a probiotic composition according to the present application as described heretofore was administered for 10 days, twice daily with a CFU count of 5 x lOelO per dose
  • Patient was thereafter administered a probiotic composition according to the present application as described heretofore, twice daily with a CFU count of 5 x 1Oe 10 per dose (or 5x10e9 CFU per gram) with improvement noted by the patient.
  • Patient experienced dramatic improvement in symptoms, and after nine months of treatment was able to taper off the corticosteroids and 5-ASA agents, and was able to be maintained on Imuran® alone.
  • a 40 year old male patient with active distal ulcerative colitis presented. While initial improvement on traditional corticosteroid treatment was seen, relapses occurred.
  • Patient was thereafter administered a probiotic composition according to the present application, achieving remission for 13 months.
  • Patient thereafter switched to a freeze-dried composition according to the present application, remaining in remission.
  • the patient remains symptom free, and has switched to a liquid probiotic composition according to the present application.
  • a 40+ year old male with active case of Ulcerative Colitis was being treated with Cortenema®. Thereafter, he was given a probiotic composition according to the present application as described heretofore, twice daily with a CFU count of 5 x lOelO per dose (or 5 x 10e9 CFU per gram). After one year on the probiotic composition, complete remission was achieved, and all medications were stopped. Remission remained for over one year, with a flare up of the condition occurring thereafter.
  • the patient was treated initially with Prednisone and a 5-ASA agent but did not have success. The patient was restarted on the probiotic composition and Cortenema® and tapered off both prednisone and the 5-ASA agent. The patient is currently taking only the probiotic composition and still remains in remission.
  • multiple patients have been administered one or more probiotic composition according to the present invention, with each patient noting significant boost to their immune systems, including relief from sinus infections, fewer incidences or shorter durations of influenza, gastroenteritis, and other respiratory infections.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une nouvelle souche de Lactobacillus delbrueckii, ssp. bulgaricus, des compositions probiotiques comprenant cette bactérie, ainsi que des procédés pour utiliser cette bactérie et/ou lesdites compositions en vue de traiter des états pathologiques et stimuler le système immunitaire.
PCT/US2007/014584 2006-06-23 2007-06-22 Nouvelle souche de lactobacillus bulgaricus et compositions la contenant Ceased WO2008002484A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/473,654 2006-06-23
US11/473,468 2006-06-23
US11/473,654 US7901925B2 (en) 2006-06-23 2006-06-23 Lactobacillus delbrueckii ssp. bulgaricus strain and compositions
US11/473,468 US20070298018A1 (en) 2006-06-23 2006-06-23 Novel lactobacillus bulgaricus strain and compositions

Publications (2)

Publication Number Publication Date
WO2008002484A2 true WO2008002484A2 (fr) 2008-01-03
WO2008002484A3 WO2008002484A3 (fr) 2008-11-13

Family

ID=38846210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/014584 Ceased WO2008002484A2 (fr) 2006-06-23 2007-06-22 Nouvelle souche de lactobacillus bulgaricus et compositions la contenant

Country Status (1)

Country Link
WO (1) WO2008002484A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050426A2 (fr) 2009-10-27 2011-05-05 "Selur Vk Holding" Eood Nouvelles souches de bactérie de l'acide lactique et leurs combinaisons pour la fabrication de préparations probiotiques
WO2012107601A1 (fr) * 2011-02-09 2012-08-16 De Las Heras Del Rio Jose Miguel Utilisation d'une souche de lactobacillus bulgaricus pour le traitement de l'immunosénescence
WO2020188181A1 (fr) 2019-03-20 2020-09-24 Vf Bioscience Nouvelles souches de bacteries lactiques favorisant l'absorption du calcium - peptides et produits associes
FR3094015A1 (fr) * 2019-03-20 2020-09-25 Vf Bioscience Nouvelles souches de bacteries lactiques favorisant l’absorption du calcium – peptides et produits associes
CN114456977A (zh) * 2022-02-17 2022-05-10 山东向日葵生物工程有限公司 一种德氏乳杆菌保加利亚亚种sf-l-18及其发酵饮品与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050426A2 (fr) 2009-10-27 2011-05-05 "Selur Vk Holding" Eood Nouvelles souches de bactérie de l'acide lactique et leurs combinaisons pour la fabrication de préparations probiotiques
EP2634269A1 (fr) 2009-10-27 2013-09-04 "Selur Vk Holding" Eood Nouvelle souche de bactéries d'acide lactique et ses combinaisons produisant des préparations de probiotiques
WO2012107601A1 (fr) * 2011-02-09 2012-08-16 De Las Heras Del Rio Jose Miguel Utilisation d'une souche de lactobacillus bulgaricus pour le traitement de l'immunosénescence
ES2386914A1 (es) * 2011-02-09 2012-09-05 José Miguel De Las Heras Del Río Uso de una cepa de lactobacillus bulgaricus para el tratamiento de la inmunosenescencia.
WO2020188181A1 (fr) 2019-03-20 2020-09-24 Vf Bioscience Nouvelles souches de bacteries lactiques favorisant l'absorption du calcium - peptides et produits associes
FR3094015A1 (fr) * 2019-03-20 2020-09-25 Vf Bioscience Nouvelles souches de bacteries lactiques favorisant l’absorption du calcium – peptides et produits associes
CN114456977A (zh) * 2022-02-17 2022-05-10 山东向日葵生物工程有限公司 一种德氏乳杆菌保加利亚亚种sf-l-18及其发酵饮品与应用

Also Published As

Publication number Publication date
WO2008002484A3 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
US7901925B2 (en) Lactobacillus delbrueckii ssp. bulgaricus strain and compositions
US11116806B2 (en) Composite probiotic lactic acid bacteria powder and preparation method and use thereof
De Vrese et al. Probiotics and prebiotics: effects on diarrhea
EP1596872B1 (fr) Compositions et procedes pour restaurer la flore bacterienne
JP4455333B2 (ja) プロバイオティック細菌：Ｌａｃｔｏｂａｃｉｌｌｕｓｆｅｒｍｅｎｔｕｍ
US6562336B2 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
US8241684B2 (en) Preventive and/or therapeutic agent for inflammatory bowel diseases
NO315542B1 (no) Enteralt diettpreparat omfattende Streptococcus thermophilus, Bifidobacterium longum og Bifidobacterium infantis, deres anvendelse samt kit
AU2019379234B2 (en) Strains, composition and method of use
TW200902040A (en) Probiotics in a pre-and/or post-surgical environment
EP2209527B1 (fr) Compositions comprenant L. acidophilus et Bifidobacterium lactis pour leur utilisation dans le traitement des troubles fonctionnels intestinaux
CN101646444A (zh) 功能性胃肠病预防和/或治疗剂
CN103228143A (zh) 用于增强肾功能的组合物和方法
JP3017493B1 (ja) 自己免疫疾患予防組成物
CN106974262A (zh) 肠道益生杆菌在治疗和预防肥胖及其相关疾病中的应用
WO2008002484A2 (fr) Nouvelle souche de lactobacillus bulgaricus et compositions la contenant
Georgieva et al. Probiotics: past, present, and future challenges
Hickson Examining the evidence for the use of probiotics in clinical practice
Arora et al. Therapeutic potential of probiotics: A ray of hope or nightmare?
US20070298018A1 (en) Novel lactobacillus bulgaricus strain and compositions
US12611434B2 (en) Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereof
US20230346856A1 (en) Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereof
CN120924424A (zh) 一种另枝杆菌及其在肠炎治疗中的用途
Horowitz Promoting gut health with probiotics: living medicines for treating digestive disorders
Kroeker et al. Treatment of Ulcerative Colitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796371

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07796371

Country of ref document: EP

Kind code of ref document: A2